Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 18/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 18/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 18/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398274 | 0.91 | CHRM2 (0.50) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6404506 | 0.91 | CHRM2 (0.48) | CHRM2CHRM1CHRM3KDM1A | |
| SCHEMBL6405805 | 0.91 | CHRM2 (0.48) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6399762 | 0.89 | CHRM2 (0.47) | CHRM2CHRM1CHRM3KDM1AEP300 | |
| SCHEMBL6400126 | 0.88 | CHRM2 (0.46) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6401033 | 0.84 | CHRM2 (0.47) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6404725 | 0.81 | CHRM2 (0.49) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6404753 | 0.80 | CHRM2 (0.56) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6404615 | 0.80 | CHRM2 (0.43) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6399176 | 0.80 | CHRM2 (0.43) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.